Literature DB >> 26674262

Phenytoin Induced Osteopathy -Too Common to be Neglected.

Milind Machhindra Patil1, Jayaprakash Sahoo2, Sadishkumar Kamalanathan3, Vivekanandan Pillai4.   

Abstract

Anticonvulsants have the broad spectrum of side effects on the bone that are collectively known as osteopathy. Anticonvulsant induced osteopathy can have detrimental consequences. We present an unusual case that uniquely highlights both adverse effects of phenytoin on bone metabolism and side effects of its overtreatment. A 29-year-old lady came for evaluation of metabolic bone disease. Since last one year, she had severe bilateral hip pain resulting in restriction of movements. She was taking phenytoin 300 mg daily for last ten years for a seizure disorder. During evaluation at another center, she was diagnosed to have vitamin D deficiency, osteomalacia and secondary hyperparathyroidism. She received recombinant parathormone, high doses of vitamin D along with phenytoin. She presented at our centre with persistent pain and hypervitaminosis D. We stopped recombinant PTH, vitamin D and changed phenytoin to levetiracetam. Her condition improved over next six months with normalization of vitamin D. Thus, patients on phenytoin should be actively screened for side effects and the appropriate preventive and correctional measures should be undertaken. While managing these side effects overtreatment should be avoided.

Entities:  

Keywords:  Anticonvulsants; Osteomalacia; Osteoporosis; Vitamin D

Year:  2015        PMID: 26674262      PMCID: PMC4668458          DOI: 10.7860/JCDR/2015/15224.6820

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  10 in total

1.  [Osteopathies in antiepileptic long-term therapy (preliminary report)].

Authors:  R Kruse
Journal:  Monatsschr Kinderheilkd       Date:  1968-06

2.  Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy.

Authors:  C Valmadrid; C Voorhees; B Litt; C R Schneyer
Journal:  Arch Neurol       Date:  2001-09

3.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.

Authors:  Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver
Journal:  J Clin Endocrinol Metab       Date:  2011-06-06       Impact factor: 5.958

4.  Prevalence and pattern of epilepsy in India.

Authors:  R Sridharan; B N Murthy
Journal:  Epilepsia       Date:  1999-05       Impact factor: 5.864

5.  Long-term anticonvulsant therapy leads to low bone mineral density--evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells.

Authors:  J Feldkamp; A Becker; O W Witte; D Scharff; W A Scherbaum
Journal:  Exp Clin Endocrinol Diabetes       Date:  2000       Impact factor: 2.949

6.  Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy.

Authors:  Dae Lim Koo; Eun Yeon Joo; Daeyoung Kim; Seung Bong Hong
Journal:  Epilepsy Res       Date:  2012-09-30       Impact factor: 3.045

Review 7.  [Antiepileptic drug-induced osteopathy. Subtypes, pathogenesis, prevention, early diagnosis and treatment].

Authors:  R Bartl
Journal:  Dtsch Med Wochenschr       Date:  2007-07-29       Impact factor: 0.628

8.  Effect of carbamazepine and valproate on bone mineral density.

Authors:  R D Sheth; C A Wesolowski; J C Jacob; S Penney; G R Hobbs; J E Riggs; J B Bodensteiner
Journal:  J Pediatr       Date:  1995-08       Impact factor: 4.406

9.  Antiepileptic drugs and bone metabolism.

Authors:  Helen A Valsamis; Surender K Arora; Barbara Labban; Samy I McFarlane
Journal:  Nutr Metab (Lond)       Date:  2006-09-06       Impact factor: 4.169

Review 10.  Vitamin D: deficiency, sufficiency and toxicity.

Authors:  Fahad Alshahrani; Naji Aljohani
Journal:  Nutrients       Date:  2013-09-13       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.